Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
  • C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H1/00—Processes for the preparation of sugar derivatives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/06—Pyrimidine radicals

Definitions

• the present invention relates to an improved process for the preparation of 4- amino-l-((2R,3R,4R s 5R)-3-fluoro-4-hydroxy-5-hydroxymethyl-3-methyl- tetrahydrofuran-2-yl)-lH-pyrimidin-2-one of the formula
• HCV Hepatitis C Virus
• Object of the present invention is to provide an improved and scalable process for the preparation of 4-amino-l-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5- hydroxymethyl-3 -methyl-tetrahydro-fiiran-2-yl)-l H-pyrimidin-2-one of the formula
• the process of the present invention comprises a) transforming an (aryl)alkanoic acid (2R,3R,4R)-2-
• R is aryl or alkyl; b) converting the (aryl)alkanoic acid (2R,3R,4R)-2-(aryl)alkanoyloxy methyl-5-chloro-4-fluoro-4-methyl-tetrahydro-furan-3-yl ester of formula III into an(aryl)alkanoic acid (2R J 3R,4R,5R)-3-(aryl)alkanoyloxy-5-(4-benzoylamino-2- oxo-2Hpyrimidin-l-yl)-4-fluoro-4-methyl-tetrahydro-furan-2-ylniethyI ester of formula I
• (aryl)alkanoic acid refers to a group RCO 2 H wherein R is either alkyl or aryl as those terms are defined herein.
• (aryl)alkanoic ester refers to a group RCO 2 R' where R is either alkyl or aryl. Most typically the R' represents the 3' and/or 5 1 position(s) of a ribose ring.
• (aryl)alkanoyl” and “(aryl)alkanoyloxy” refer to the groups RCO- and RCOO- respectively, where R is as described previously.
• (aryl)alkanoyloxymethyl refers a group RCOOCH2- where R is as described previously.
• alkyl denotes an unbranched or branched chain, saturated, monovalent hydrocarbon residue containing 1 to 10 carbon atoms.
• aryl refers to phenyl group.
• R has the meaning of phenyl.
• step a) comprises a reduction in the presence of a reducing agent and a subsequent chlorination in the presence of chlorinating agent.
• Suitable reducing agent is sodium ⁇ /.y-(2-methoxyethoxy) (2,2,2- trifluoroethoxy) aluminum hydride which is commercially available under the tradename RedAl® as a solution in toluene.
• the reduction usually takes place in an organic solvent such as in a halogenated hydrocarbon like dichloromethane at a reaction temperature of below 0 0 C, preferably below -5°C.
• the chlorinating agent is as a rule selected from sulfuryl chloride, thionyl chloride or phosphorus oxychloride.
• sulfuryl chloride in the presence of catalytic amounts of tetrabutyl ammonium bromide is used.
• the O-trimethyl silyl-N4-benzoylcytosin may be prepared in situ by reacting N-benzoyl cytosine with hexamethyldisilazan in the presence of ammonium sulfate in chlorobenzene under reflux conditions.
• the reaction is usually performed at elevated temperature, for instance at about 70°C until the coupling is complete.
• Suitable bases are organic bases like alkali metal alkoxides. Preferably sodium methoxide in methanol as solvent is used.
• the reaction is performed at elevated temperature, for instance at about 50 0 C until the hydrolysis is complete.
• the 4-amino-l-((2R J 3R,4R,5R)-3-fluoro-4-hydroxy-5-hydroxymethyl-3- methyltetrahydro-furan-2-yl)-lH-pyrimidin-2-one of the formula IV can be isolated following methods known to the skilled in the art.
• step al The asymmetric hydroxylation in step al) was discovered to be best carried out with sodium permanganate in the presence of ethylene glycol, sodium bicarbonate in acetone at a temperature of -20 to 0° C which afforded the diol in 60-64% on pilot plant scale.
• Starting compound (V) can be obtained from (lS,2S)-l,2- ⁇ z>((R)-2,2-dimethyl-[l,3]dioxolan-4-yl)-ethane- 1,2-diol (C. R. Schmid and J. D. Bryant, Jerry D., Org. Syn. 1995 72:6-13) by oxidative cleavage of the diol and treating the resulting aldehyde with 2- (triphenyl- ⁇ 5 -phosphanylidene)-propionic acid ethyl ester.
• the cyclic sulfate (VIII) can be prepared by cyclization of the vicinal diol with e.g. thionyl chloride in step bl) and oxidation of the resulting cyclic sulfite (VII) in step cl) to the corresponding sulfate (VIII) with NaOCl in the presence of MeCN. It has been found that the cyclic sulfates can be stabilized during processing by the addition of a trialkylamine such as TEA or DIPEA at 2-10 mole % relative to the cyclic sulfate.
• a trialkylamine such as TEA or DIPEA
• DSC Differential scanning calorimetry
• the base used for step fl) includes, but is not limited to the following list: imidazole, pyridine, DMAP, TEA, DIPEA, l,4-diazabicyclo[2,2,2]octane.
• the solvent used for step fl) includes, but is not limited to acetonitrile, pyridine, DCM, chloroform, DCE, THF.
• Trifluoroethanol (4.08 kg) is added slowly to a cold solution (-15 0 C) of RED-AL® solution (12.53 kg) and toluene (21.3 kg) while maintaining the reaction temperature at or below -10 0 C.
• the modified RED-AL reagent mixture (30.1 kg out of the 37.6 kg prepared) is added slowly to a pre-cooled solution (-15 0 C) of fluorolactone dibenzoate 10 (10 kg) in DCM (94.7 kg) while maintaining reaction temperature at or below -10 0 C.
• reaction mixture is then stirred at ambient temperature for ca 1 h to ensure hydrolytic decomposition of excess sulfuryl chloride and the phases are separated.
• organic layer is washed with a dilute solution of citric acid (prepared by dissolving 15.5 kg of citric acid in 85 L of water) and then with dilute KOH solution (prepared by dissolving 15 kg of 50% KOH in
• the anhydrous solution of 30 in chlorobenzene (as prepared) and stannic chloride (28.2 kg) are added to this concentrate.
• the reaction mixture is maintained at about 70 0 C until the desired coupling reaction is complete (ca. 10 h) as determined by in process HPLC.
• the reaction mixture is cooled to ambient temperature and diluted with DCM (121 kg). This solution is added to a suspension of solid NaHCO 3 (47 kg) and CELITE® (9.4 kg) in DCM
• a slurry of 14 (14.7 kg) in MeOH (92.6 kg) is treated with catalytic amounts of methanolic sodium methoxide (0.275 kg).
• the reaction mixture is heated to ca. 50 0 C and aged (ca 1 h) until the hydrolysis is complete.
• the reaction mixture is quenched by addition of isobutyric acid (0.115 kg).
• the resulting solution is concentrated under moderate vacuum and then residual solvents are replaced with IPA (80 kg).
• the batch is distilled to a volume of ca. 50 L.
• the resulting slurry is heated to ca. 80 0 C and then cooled slowly to ca. 5°C and aged (ca. 2 h).
• the precipitated product is isolated by filtration, washed with IPA (16.8 kg) and dried in an oven at 70 0 C in vacuo to afford 6.26 kg (88.9%) of 18 which assayed at 99.43% pure
• a suspension of 22 (10 kg, CAS Reg. No. 81997-76-4), ethylene glycol (11.6 kg), solid NaHCO 3 (11.8 kg) and acetone (150 L) is cooled to ca. -15° C.
• a solution of 36% aqueous NaMnO4 (19.5 kg) is charged slowly (over 4 h) to the suspension maintaining reaction temperature at or below -10 0 C.
• an aliquot of the reaction mixture (ca. 5 mL) is quenched with 25% aqueous sodium bisulfite (ca. 15 mL).
• a portion of resulting slurry is filtered and submitted for GC analysis to check the progress of the reaction.
• reaction mixture is quenched by slow (over 40 min) addition of cooled (ca. 0 0 C) 25% aqueous NaHSCb (60 L). The temperature of the reaction mixture is allowed to reach 4°C during the quench.
• CELITE® (ca. 2.5 kg) is then slurried in acetone (8 kg) and added to the dark brown reaction mixture. The resulting slurry is aged at ambient temperature to obtain light tan slurry. The slurry is filtered, and the filter cake is washed with acetone (3 x 39 kg). The combined filtrate is concentrated by vacuum distillation (vacuum approximately 24 inches of Hg (ca. 810 mbar); max pot temperature is 32°C) to remove the acetone.
• the aqueous concentrate is extracted with EtOAc (3 x 27 kg), and the combined organic extracts were washed with water (25 L). The organic phase is then concentrated by atmospheric distillation and EtOAc is replaced with toluene. The volume of the batch is adjusted to ca. 20 L. Heptane (62 kg) is added and the batch cooled to ca. 27° C to initiate crystallization. The batch is then cooled to -10° C. After aging overnight at -10° C 5 the product is filtered, washed with 10% toluene in heptane and dried at 50 0 C under vacuum to afford 6.91 kg (59.5%) of 24 (CA RN 81997-76-4) as a white crystalline solid.
• Steps 1 & 2 - A dry, clean vessel was charged with 24 (6.0 kg), isopropyl acetate (28.0 kg), MeCN (3.8 kg) and TEA (5.4 kg). The mixture was cooled to 5-10 0 C, and thionyl 10 chloride (3.2 kg) was added slowly while cooling the solution to maintain the temperature below 20 0 C. The mixture was stirred until no starting material was left (GC analysis). The reaction was typically complete within 30 min after addition is complete. To the mixture was added water (9 kg) and after stirring, the mixture was allowed to settle. The aqueous phase was discarded and the organic phase was washed with a mixture of water (8 kg) and saturated NaHCO 3 (4 kg ) solution.
• Step 3 To the concentrated oil from step 2 containing 26 was 5 added TEA

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Saccharide Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Priority Applications (15)

Applications Claiming Priority (2)

Publications (1)

Family

ID=39111500

Family Applications (1)

Country Status (18)

Cited By (25)

Families Citing this family (55)

Citations (4)

Family Cites Families (17)

• 2007
  • 2007-10-05 WO PCT/US2007/021548 patent/WO2008045419A1/en not_active Ceased
  • 2007-10-05 RU RU2009117396/04A patent/RU2421461C2/ru not_active IP Right Cessation
  • 2007-10-05 PL PL07839369T patent/PL2084174T3/pl unknown
  • 2007-10-05 DK DK07839369.1T patent/DK2084174T3/da active
  • 2007-10-05 CA CA2666098A patent/CA2666098C/en active Active
  • 2007-10-05 KR KR1020097008991A patent/KR101057239B1/ko active Active
  • 2007-10-05 CN CN200780037855.XA patent/CN101600725B/zh active Active
  • 2007-10-05 MX MX2009003795A patent/MX2009003795A/es active IP Right Grant
  • 2007-10-05 AU AU2007307057A patent/AU2007307057B2/en active Active
  • 2007-10-05 SI SI200731311T patent/SI2084174T1/sl unknown
  • 2007-10-05 PT PT78393691T patent/PT2084174E/pt unknown
  • 2007-10-05 EP EP07839369.1A patent/EP2084174B1/en active Active
  • 2007-10-05 JP JP2009532372A patent/JP5252459B2/ja active Active
  • 2007-10-05 US US12/444,608 patent/US8912321B2/en active Active
  • 2007-10-05 BR BRPI0719174A patent/BRPI0719174A2/pt not_active IP Right Cessation
  • 2007-10-05 ES ES07839369T patent/ES2429290T3/es active Active
  • 2007-10-10 US US11/973,748 patent/US20080139802A1/en not_active Abandoned
• 2009
  • 2009-04-07 IL IL198086A patent/IL198086A/en active IP Right Grant
  • 2009-04-13 GT GT200900080A patent/GT200900080A/es unknown

Patent Citations (4)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events